MCL Literature Feed

This retrospective study suggests a 1-day bendamustine regimen for MCL offers comparable progression-free survival to the standard 2-day schedule but with significantly less neutropenia and adverse events.

This 20-year Taiwanese retrospective study confirms that frontline rituximab, intensive chemotherapy, and autologous transplant are associated with improved survival, validating these established strategies in a real-world Asian cohort.

This large retrospective study of 476 MCL patients aged ≥80 provides crucial real-world outcome data, informing treatment selection and expectations in the very elderly population.

In newly diagnosed MCL, PET/CT-based bone marrow assessment has greater prognostic value than biopsy and is incorporated into a new MCL-PET-I index for improved risk stratification.

This retrospective case series strengthens the link between ibrutinib and delayed-onset uveitis, a potentially vision-threatening toxicity that resolves upon drug cessation, highlighting a key clinical management consideration.

Real-world, intention-to-treat data from the French DESCAR-T registry confirms brexucabtagene autoleucel efficacy in relapsed/refractory MCL, providing practical outcomes for all patients intended for treatment.

This large, single-center retrospective study characterizes the aggressive nature and poor outcomes of MCL with cutaneous involvement, providing crucial real-world data for managing this rare presentation.

This meta-analysis quantifies the poor prognosis (median OS ~9 months) for r/r MCL patients post-covalent BTKi treated with standard therapies, highlighting the superior efficacy of brexucabtagene autoleucel.

Real-world US Medicare data shows elderly MCL patients post-cBTKi have a dismal median OS of 9.4 months and high costs, highlighting the urgent need for effective therapies.

A meta-analysis of 7,604 patients found mantle cell lymphoma has the highest non-relapse mortality (10.6%) post-CAR-T, with infections being the primary cause, not CAR-T-specific toxicities.

In younger, BTKi-naïve MCL patients with late relapse (>24 months), second-line BTKi significantly improved PFS and OS versus chemoimmunotherapy, establishing it as the preferred approach in this setting.

This large, real-world French database study on ibrutinib focuses exclusively on patients with CLL, providing no specific data or insights relevant to mantle cell lymphoma.

A high monocyte-to-platelet ratio (MPR ≥ 3) at diagnosis is a novel, independent prognostic biomarker for inferior progression-free survival in transplant-ineligible mantle cell lymphoma patients.

This large, real-world study confirms cytarabine-based induction provides the longest front-line PFS (68 months), while second-line chemotherapy outcomes are poor (14 months PFS), highlighting the need for novel agents.

This multicenter retrospective study analyzes real-world maintenance strategies in mantle cell lymphoma, providing evidence to guide treatment selection and duration after initial therapy.

This multicenter real-world study demonstrates that CAR-T therapy can be an effective treatment for MCL patients with secondary CNS involvement, a population with historically poor outcomes.

This paper likely provides a retrospective or real-world analysis of the incidence, types, and risk factors for infections in MCL, informing clinical decisions on prophylaxis and supportive care.

This large US prospective cohort study suggests outdoor air pollution is a potential environmental risk factor for developing specific hematologic cancer subtypes, highlighting the importance of subtype-specific etiological research.

Bendamustine is a feasible alternative lymphodepletion for brexu-cel in MCL, showing comparable efficacy to standard cy/flu with less cytopenia, providing a critical option during drug shortages.

A qualitative study of Japanese MCL patients reveals that convenience, quality of life, and shared decision-making are key treatment preferences, alongside efficacy and safety, guiding personalized care.

In a large real-world cohort, mantle cell lymphoma patients exhibited higher CAR19 expansion than other lymphomas, which directly correlated with increased toxicity and significantly higher steroid requirements.

This UK real-world, intention-to-treat analysis of brexu-cel confirms high efficacy in infused patients but reveals a 30% attrition rate before infusion and significant non-relapse mortality from infection.

In young, newly diagnosed MCL, first-line rituximab, bendamustine, and cytarabine (R-BAP) plus a BTK inhibitor improved complete response and PFS over standard R-CHOP/R-DHAP in a real-world setting.

Outpatient autologous stem cell transplantation is a feasible consolidation strategy for advanced MCL in a low-income, Latin American setting, providing important real-world evidence for resource-constrained systems.

In a European compassionate use program, pirtobrutinib demonstrated a 67% overall response rate and good safety in heavily pretreated, BTKi-exposed relapsed/refractory MCL, supporting its real-world clinical utility.

Real-world registry data from Ukraine (2019-2021) reports a 3-year overall survival of 61% for newly diagnosed MCL patients, providing a crucial benchmark for outcomes in this region.

The EHA/EBMT ICAHT grading system better predicts severe infections and mortality post-CAR-T than CTCAE, which is highly relevant as MCL patients showed the highest rates of severe hematotoxicity.

Real-world UK data show first-line ibrutinib is effective and tolerable for older MCL patients, but high-risk subgroups (TP53-mutated, blastoid) have significantly inferior survival, highlighting an unmet need.

This large SEER database study identifies being unmarried, particularly widowed, as an independent negative prognostic factor for survival in MCL, underscoring the need for enhanced psychosocial support.

This large retrospective study of orbital lymphomas identifies mantle cell lymphoma as a rare subtype but provides no specific clinical or prognostic data for this particular presentation.